We are upgrading the repository! We will continue our upgrade in February 2025 - we have taken a break from the upgrade to open some collections for end-of-semester submission. The MS-GIST Master's Reports, SBE Senior Capstones, and UA Faculty Publications collections are currently open for submission. Please reach out to repository@u.library.arizona.edu with your questions, or if you are a UA affiliate who needs to make content available in another collection.
SOX17 Deficiency Mediates Pulmonary Hypertension At the Crossroads of Sex, Metabolism, and Genetics
Author
Sangam, S.Sun, X.
Schwantes-An, T.-H.
Yegambaram, M.
Lu, Q.
Shi, Y.
Cook, T.
Fisher, A.
Frump, A.L.
Coleman, A.
Sun, Y.
Liang, S.
Crawford, H.
Lutz, K.A.
Maun, A.D.
Pauciulo, M.W.
Karnes, J.H.
Chaudhary, K.R.
Stewart, D.J.
Langlais, P.R.
Jain, M.
Alotaibi, M.
Lahm, T.
Jin, Y.
Gu, H.
Tang, H.
Nichols, W.C.
Black, S.M.
Desai, A.A.
Affiliation
Division of Endocrinology, College of Medicine, University of ArizonaIssue Date
2023-01-30Keywords
16a-hydroxyestronehypoxia-inducible factor 2a
metabolism
pulmonary arterial hypertension
SRY-related HMG-box 17
Metadata
Show full item recordPublisher
American Thoracic SocietyCitation
Sangam, S., Sun, X., Schwantes-An, T. H., Yegambaram, M., Lu, Q., Shi, Y., ... & Desai, A. A. (2023). SOX17 deficiency mediates pulmonary hypertension: at the crossroads of sex, metabolism, and genetics. American journal of respiratory and critical care medicine, 207(8), 1055-1069.Rights
© 2023 by the American Thoracic Society. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0.Collection Information
This item from the UA Faculty Publications collection is made available by the University of Arizona with support from the University of Arizona Libraries. If you have questions, please contact us at repository@u.library.arizona.edu.Abstract
Rationale: Genetic studies suggest that SOX17 (SRY-related HMG-box 17) deficiency increases pulmonary arterial hypertension (PAH) risk. Objectives: On the basis of pathological roles of estrogen and HIF2a (hypoxia-inducible factor 2a) signaling in pulmonary artery endothelial cells (PAECs), we hypothesized that SOX17 is a target of estrogen signaling that promotes mitochondrial function and attenuates PAH development via HIF2a inhibition. Methods: We used metabolic (Seahorse) and promoter luciferase assays in PAECs together with the chronic hypoxia murine model to test the hypothesis. Measurements and Main Results: Sox17 expression was reduced in PAH tissues (rodent models and from patients). Chronic hypoxic pulmonary hypertension was exacerbated by mice with conditional Tie2-Sox17 (Sox17EC2/2) deletion and attenuated by transgenic Tie2-Sox17 overexpression (Sox17Tg). On the basis of untargeted proteomics, metabolism was the top pathway altered by SOX17 deficiency in PAECs. Mechanistically, we found that HIF2a concentrations were increased in the lungs of Sox17EC2/2 and reduced in those from Sox17Tg mice. Increased SOX17 promoted oxidative phosphorylation and mitochondrial function in PAECs, which were partly attenuated by HIF2a overexpression. Rat lungs in males displayed higher Sox17 expression versus females, suggesting repression by estrogen signaling. Supporting 16a-hydroxyestrone (16aOHE; a pathologic estrogen metabolite)-mediated repression of SOX17 promoter activity, Sox17Tg mice attenuated 16aOHE-mediated exacerbations of chronic hypoxic pulmonary hypertension. Finally, in adjusted analyses in patients with PAH, we report novel associations between a SOX17 risk variant, rs10103692, and reduced plasma citrate concentrations (n = 1, 326). Conclusions: Cumulatively, SOX17 promotes mitochondrial bioenergetics and attenuates PAH, in part, via inhibition of HIF2a. 16aOHE mediates PAH development via downregulation of SOX17, linking sexual dimorphism and SOX17 genetics in PAH. Copyright © 2023 by the American Thoracic Society.Note
Open access articleISSN
1073-449XPubMed ID
36913491Version
Final Published Versionae974a485f413a2113503eed53cd6c53
10.1164/rccm.202203-0450OC
Scopus Count
Collections
Except where otherwise noted, this item's license is described as © 2023 by the American Thoracic Society. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0.
Related articles
- Sox17 Deficiency Promotes Pulmonary Arterial Hypertension via HGF/c-Met Signaling.
- Authors: Park CS, Kim SH, Yang HY, Kim JH, Schermuly RT, Cho YS, Kang H, Park JH, Lee E, Park H, Yang JM, Noh TW, Lee SP, Bae SS, Han J, Ju YS, Park JB, Kim I
- Issue date: 2022 Oct 28
- SOX17 Enhancer Variants Disrupt Transcription Factor Binding And Enhancer Inactivity Drives Pulmonary Hypertension.
- Authors: Walters R, Vasilaki E, Aman J, Chen CN, Wu Y, Liang OD, Ashek A, Dubois O, Zhao L, Sabrin F, Cebola I, Ferrer J, Morrell NW, Klinger JR, Wilkins MR, Zhao L, Rhodes CJ
- Issue date: 2023 May 23
- E2F1 Mediates SOX17 Deficiency-Induced Pulmonary Hypertension.
- Authors: Yi D, Liu B, Ding H, Li S, Li R, Pan J, Ramirez K, Xia X, Kala M, Ye Q, Lee WH, Frye RE, Wang T, Zhao Y, Knox KS, Glembotski CC, Fallon MB, Dai Z
- Issue date: 2023 Nov
- SOX17 is a Critical Factor in Maintaining Endothelial Function in Pulmonary Hypertension by an Exosome-Mediated Autocrine Manner.
- Authors: Zou X, Liu T, Huang Z, Zhou W, Yuan M, Zhao H, Pan Z, Chen P, Shao Y, Hu X, Zhang S, Zheng S, Zhang Y, Huang P
- Issue date: 2023 May
- Activity of the estrogen-metabolizing enzyme cytochrome P450 1B1 influences the development of pulmonary arterial hypertension.
- Authors: White K, Johansen AK, Nilsen M, Ciuclan L, Wallace E, Paton L, Campbell A, Morecroft I, Loughlin L, McClure JD, Thomas M, Mair KM, MacLean MR
- Issue date: 2012 Aug 28